Tuesday, February 22, 2022 10:44:20 AM
Thank You Gat:0)))
=========
User avatar
level 1
Biomedical_trader
OP
·
32 min. ago
Clinical Research Associate
This article was originally found by u/RealStockPicks I thought it might be a good idea to call it out and explain why it's so important and relevant for Bucillamine.
Bucillamine has two thiol groups, you might think that would make it twice as effective as NAC, but much of the negative consequences of oxidative stress that happens in our body revolve around dimers. When oxidized, 2 glutathione (GSH) link together forming a "dimer" that is called GSSG for short because the hydrogen gets removed and the two GSH molecules are now linked by the sulfur atoms.
The researchers here found that NAC can only perform certain functions for COVID when it is a dimer. Since each Bucillamine molecule has 2 thiol groups, it is always prepared to prevent blood clots and interact with the body's chemistry.
=========
User avatar
level 1
Biomedical_trader
OP
·
32 min. ago
Clinical Research Associate
This article was originally found by u/RealStockPicks I thought it might be a good idea to call it out and explain why it's so important and relevant for Bucillamine.
Bucillamine has two thiol groups, you might think that would make it twice as effective as NAC, but much of the negative consequences of oxidative stress that happens in our body revolve around dimers. When oxidized, 2 glutathione (GSH) link together forming a "dimer" that is called GSSG for short because the hydrogen gets removed and the two GSH molecules are now linked by the sulfur atoms.
The researchers here found that NAC can only perform certain functions for COVID when it is a dimer. Since each Bucillamine molecule has 2 thiol groups, it is always prepared to prevent blood clots and interact with the body's chemistry.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
